RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Fourth Hospital of Hebei Medical University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07635342, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to 65 years; sex: women only

    Registered eligibility fields

  2. Patients with previously untreated invasive breast cancer confirmed by pathological examination.

    Inclusion criterion 2

    HER2-positive breast cancer, defined as immunohistochemistry (IHC) 3+ or IHC 2+ with HER2 gene amplification confirmed by in situ hybridization (ISH), regardless of hormone receptor status.

    Inclusion criterion 3

  3. Clinical stage T2N0-3M0 or any T/N1-N3M0 according to the 8th edition of the American Joint Committee on Cancer (AJCC) staging system.

    Inclusion criterion 4

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

    Inclusion criterion 6

  5. Hemoglobin ≥100 g/L.

    Inclusion criterion 8

    Absolute neutrophil count ≥1.5 × 10\^9/L.

    Inclusion criterion 9

    Platelet count ≥100 × 10\^9/L.

    Inclusion criterion 10

    Total bilirubin ≤1 × upper limit of normal (ULN).

    Inclusion criterion 11

    Alanine aminotransferase and aspartate aminotransferase ≤1.5 × ULN.

    Inclusion criterion 12

    Alkaline phosphatase ≤2.5 × ULN.

    Inclusion criterion 13

    Blood urea nitrogen and serum creatinine ≤1.5 × ULN.

    Inclusion criterion 14

  6. At least one measurable lesion according to RECIST version 1.1.

    Inclusion criterion 5

  7. Breast cancer not confirmed by pathological examination.

    Exclusion criterion 5

    History of other malignancies within 5 years, except cured carcinoma in situ of the cervix.

    Exclusion criterion 6

    History of immunodeficiency, including positive HIV test, hepatitis C virus infection, active hepatitis B virus infection, other acquired or congenital immunodeficiency diseases, or history of organ transplantation.

    Exclusion criterion 11

  8. Pregnant or breastfeeding women, women of childbearing potential with a positive baseline pregnancy test, or women of childbearing potential unwilling to use effective contraception throughout the study.

    Exclusion criterion 13

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07635342, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Female patients aged 18 to 65 years.
  • Patients with previously untreated invasive breast cancer confirmed by pathological examination.
  • HER2-positive breast cancer, defined as immunohistochemistry (IHC) 3+ or IHC 2+ with HER2 gene amplification confirmed by in situ hybridization (ISH), regardless of hormone receptor status.
  • Clinical stage T2N0-3M0 or any T/N1-N3M0 according to the 8th edition of the American Joint Committee on Cancer (AJCC) staging system.
  • At least one measurable lesion according to RECIST version 1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Adequate organ function, meeting all of the following criteria:
  • Hemoglobin ≥100 g/L.
  • Absolute neutrophil count ≥1.5 × 10\^9/L.
  • Platelet count ≥100 × 10\^9/L.
  • Total bilirubin ≤1 × upper limit of normal (ULN).
  • Alanine aminotransferase and aspartate aminotransferase ≤1.5 × ULN.
  • Alkaline phosphatase ≤2.5 × ULN.
  • Blood urea nitrogen and serum creatinine ≤1.5 × ULN.
  • Left ventricular ejection fraction ≥55% by echocardiography.
  • Women of childbearing potential must have a negative serum pregnancy test within 7 days before enrollment and agree to use appropriate contraception during the study and for 8 weeks after the last dose of study treatment.
  • Patients must voluntarily participate in the study, sign the informed consent form, have good compliance, and be willing to cooperate with follow-up.

Exclusion Criteria:

  • Prior receipt of any anti-tumor therapy, including chemotherapy, radiotherapy, molecular targeted therapy, or endocrine therapy.
  • Concurrent receipt of any other anti-tumor therapy.
  • Bilateral breast cancer, inflammatory breast cancer, or occult breast cancer.
  • Stage IV breast cancer.
  • Breast cancer not confirmed by pathological examination.
  • History of other malignancies within 5 years, except cured carcinoma in situ of the cervix.
  • Severe dysfunction of major organs, including the heart, liver, or kidney.
  • Inability to swallow, chronic diarrhea, intestinal obstruction, or other factors that may affect drug administration or absorption.
  • Participation in another drug clinical trial within 4 weeks before enrollment.
  • Known history of allergy to any component of the study treatment.
  • History of immunodeficiency, including positive HIV test, hepatitis C virus infection, active hepatitis B virus infection, other acquired or congenital immunodeficiency diseases, or history of organ transplantation.
  • History of any cardiac disease, including clinically significant arrhythmia requiring medication, myocardial infarction, heart failure, or any other cardiac disease judged by the investigator to make the patient unsuitable for this study.
  • Pregnant or breastfeeding women, women of childbearing potential with a positive baseline pregnancy test, or women of childbearing potential unwilling to use effective contraception throughout the study.
  • Serious concomitant diseases that, in the investigator's judgment, may compromise patient safety or affect completion of the study, including but not limited to uncontrolled severe hypertension, severe diabetes mellitus, or active infection.
  • Clear history of neurological or psychiatric disorders, including epilepsy or dementia.
  • Any other condition that, in the investigator's opinion, makes the patient unsuitable for participation in this study.

Quoted from ClinicalTrials.gov, NCT07635342, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07635342, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07635342